JobWatch is a job posting and career development site designed exclusively for clinical research professionals of all levels. Job seekers can easily post and update resumes, apply directly for open positions and register for e-mail alerts announcing new positions. It is also the perfect resource to learn more about upcoming conferences on clinical research-related topics or register for training and academic degree programs for career development and advancement.
Sign up for your free account and find your next opportunity today!
Reach more professionals with your job posting. Jobs posted on JobWatch also appear complementary on ACRPs Career Center as part of our partnership. Your job listing receives extra exposure to the industry's largest community of clinical research professionals. Post Jobs Today.
Shire will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire’s lease begins in Q3, 2018, with occupancy anticipated for Q1, 2019.
TKL Research, a dermatology specialty CRO, has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS. Upon closing, TKL’s CTD will become part of Novella Clinical, a Quintiles company. Moving forward, TKL Research will retain its Research Clinics Division (RCD) as TKL Research, which operates full-service inpatient and outpatient phase I facilities in northern New Jersey.
Biogen has announced the addition of two members to the executive management team of Bioverativ, Biogen’s planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017.
The Delaware BioScience Association (Delaware Bio) has announced that its founding President Bob Dayton is retiring after 10 years of achieving continuous growth and increasing influence. As of February 1, Dayton will be succeeded by Helen Stimson, who will leave her current role as vice president and general manager of the Chemistries and Supplies Division at Agilent Technologies at the end of the month.